ImmunityBio
IBRX
210 hedge funds and large institutions have $239M invested in ImmunityBio in 2025 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 76 increasing their positions, 41 reducing their positions, and 32 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 41
38% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 32
13% more capital invested
Capital invested by funds: $212M → $239M (+$27.6M)
4% more funds holding
Funds holding: 201 → 210 (+9)
2% less ownership
Funds ownership: 11.32% → 9.33% (-2%)
43% less call options, than puts
Call options by funds: $7.5M | Put options by funds: $13.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.14M |
| 2 |
Citigroup
New York
|
+$7.06M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$2.57M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.35M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.68M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.67M |
| 3 |
Morgan Stanley
New York
|
-$6.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$3.13M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.71M |
IBRX Hedge Fund Activity: Q1 2025 in Review
210 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2025, worth a combined $239M — up 13% from $212M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new IBRX positions and 32 closed out — a net gain of 12 holders — while 76 added to existing stakes and 41 trimmed.
The largest buyer was Vanguard Group, adding an estimated $9.14M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $7.68M sold.
- 210 institutional investors held ImmunityBio (IBRX) as of Q1 2025, up from 201 in Q4 2024.
- Funds reported $239M of ImmunityBio stock for Q1 2025, up 13% quarter-over-quarter.
- 44 funds opened new ImmunityBio positions in Q1 2025 and 32 closed out, a net change of +12 holders.
- The largest ImmunityBio buyer in Q1 2025 was Vanguard Group, an estimated $9.14M added.
- The largest ImmunityBio seller in Q1 2025 was Cormorant Asset Management, an estimated $7.68M sold.
Based on aggregated 13F filings for Q1 2025.